Project Grant R21AI188334
Award Date
11/13/24
Completion Date
10/31/26
Dollars Obligated
$242K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10012, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to President and Fellows of Harvard College to develop novel antibiotic candidates that target the lipoprotein transport pathway in Gram-negative bacteria. The research aims to synthesize and evaluate a modular platform of antibiotics with improved potency and optimized...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) provides $1,120,070 over 5 years starting July 2025 to the University of Oklahoma. The funding will support the development of new tools and resources to optimize the intracellular accumulation of antibacterial agents effective against Gram-negative pathogens. Key objectives include generating predictive machine...
This Project Grant award of $747,763 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of small molecule inhibitors of the LPXH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The goal is to design and synthesize potent LPXH inhibitors with optimal drug-like properties, and demonstrate the safety and efficacy of a lead LPXH inhibitor candidate in a murine sepsis...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $451,000.00 to The Trustees of Princeton University to conduct research aimed at identifying new antimicrobial targets in Gram-negative bacterial pathogens. The key products of this 2-year project involve: 1) Identifying a small molecule inhibitor of methionine synthase that demonstrates chemical synthetic lethality...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
This federal Project Grant award of $254,478 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to overcome them. The award recipient, The University of Texas Southwestern Medical Center, will investigate resistance to these novel antibacterial compounds called...
This Project Grant award of $438,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop new tools to facilitate drug discovery for pathogen proteasomes. The funded project at the University of California, San Diego aims to address two key bottlenecks in advancing research on parasite proteasomes - the difficulty in isolating and purifying parasite 20S proteasome enzymes,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid antibiotic susceptibility testing platform. The platform will isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes, enabling clinicians to quickly determine appropriate targeted...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is focused on exploring synergistic combinations of aminoglycoside antibiotics to combat multidrug-resistant (MDR) gram-negative bacteria. The $475,036 award, granted on Apr 11, 2025, aims to: 1) Identify dual-aminoglycoside combinations that demonstrate synergistic and maximally suppressive activity against MDR bacterial isolates, while evaluating...